Source: School Course 2012 - Lung Transplantation



Rating:

Share or cite this content

Citations should be made in the following way:
G.M. Verleden (Leuven, Belgium). Actual role of azithromycin: when and how. School Course 2012 - Lung Transplantation

Member's Comments

No comment yet.

Related content which might interest you: The role of moxifloxacin in tuberculosis therapy Source: Eur Respir Rev 2015; 25: 19-28 Year: 2016 Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019 Year: 2020 Late Breaking Abstract - Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid - Data from 38,820 outpatients. Source: International Congress 2019 – Comorbidities galore in respiratory patients Year: 2019 Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011 Comparative efficacy and safety of five-day moxifloxacin and seven-day ceftriaxone treatment of AECB: results of the SMART study Source: Eur Respir J 2002; 20: Suppl. 38, 545s Year: 2002 Achieving asthma control: the key role of inhalers Source: Breathe 2008; 5: 120-131 Year: 2008 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004 Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective Source: Eur Respir J 2010; 35: 936-938 Year: 2010 Precision medicine in tuberculosis treatment – a role for pharmacogenetics? Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Efficacy of moxifloxacin in TB resistant to isoniazid Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013 Treatment guidelines for CAP and the role of macrolides Source: Annual Congress 2004 - Developments in the management of lower respiratory tract infections Year: 2004 Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012 Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019 Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis. Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021